By 2020, both GLP‐1 receptor agonists and SGLT‐2 inhibitors were more commonly prescribed in incident patients with type 2 diabetes than DPP‐4 inhibitors. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.